Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasm Metastasis 3Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Adenocarcinoma 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × STA 9090 × Clear all
NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡